COMIC66 USAF E-8C joint Stars coming out of the south Chyyyna sea back to Okinawa

The E-8C Joint Surveillance Target Attack Radar System, or Joint STARS, is an airborne battle management, command and control, intelligence, surveillance and reconnaissance platform. Its primary mission is to provide theater ground and air commanders with ground surveillance to support attack operations and targeting that contributes to the delay, disruption and destruction of enemy forces. The E-8C is a modified Boeing 707-300 series commercial airframe extensively remanufactured and modified with the radar, communications, operations and control subsystems required to perform its operational mission.

https://www.af.mil/About-Us/Fact-Sheets/Display/Article/104507/e-8c-joint-stars/

GHOST52 US Navy G5 wn from Wake Island to Okinawa-origin of Oahu. Using that upgraded runway.

Major Airfield Expansion On Wake Island Seen By Satellite As U.S. Preps For Pacific Fight

https://www.thedrive.com/the-war-zone/34404/big-airfield-expansion-on-wake-island-seen-by-satellite-as-u-s-preps-for-pacific-fight

>>9983207

nkarta Therapeutics bought by RA Capital Mgmt: $59.99m-July14

nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

https://www.marketscreener.com/NKARTA-INC-109581179/news/Nkarta-Announces-Closing-of-Upsized-Initial-Public-Offering-and-Exercise-in-Full-of-Underwriters-Op-30923956/

The forehead club

https://www.racap.com/about-us

from July 10

Therapeutics Acquisition Corp., Sponsored by RA Capital Management, L.P., Announces Closing of $135.7 Million Initial Public Offering, Including the Full Exercise of the Underwriter’s Option To Purchase Additional Shares

https://www.businesswire.com/news/home/20200710005428/en/Therapeutics-Acquisition-Corp.-Sponsored-RA-Capital-Management

Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety, and mbIL-15. This platform is modular, which enables optimization of different ways to enhance the natural signaling of engineered cells, as well as the ability to attach and optimize new targeting receptors. The Company’s lead product candidates are NKX101 and NKX019.

https://www.marketscreener.com/NKARTA-INC-109581179/company/

https://www.finviz.com/insidertrading.ashx?oc=1346824&tc=7&b=2

>>9983379

>>9983565